Cargando…

Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors In Type 2 Diabetes Mellitus Patients

Background: SGLT-2 inhibitors are a group of oral medications that work independently of insulin working as anti-diabetics by enhancing the excretion of glucose. The purpose of our study was to assess the improvement in terms of HbA1c, weight, blood pressure and BMI and the hepatics and renal effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saleem, Muhammad, Ram, Nanik, Khan, Sajjad Ali, Suchal, Zafar Aleem, Mehdi Khan, Muhammad Mustansir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089694/ http://dx.doi.org/10.1210/jendso/bvab048.953

Ejemplares similares

Clinical and biochemical outcomes of Sodium-Glucose CoTransporter-2 (SGLT2) Inhibitors in Type-2 Diabetes Mellitus Patients as a fourth oral anti diabetic medicine
por: Saleem, Muhammad, et al.
Publicado: (2022)

Clinical and Biochemical Characteristics of Male Idiopathic Hypogonadotropic Hypogonadism Patients: A Retrospective Cross Sectional Study
por: Saleem, Muhammad, et al.
Publicado: (2023)

Sodium Glucose Co-Transporter2 (SGLT2) Inhibition for Refractory Hypomagnesemia in Monogenic Diabetes Type 5 (MODY 5)
por: Paul, Anju A, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Euglycemic DKA Associated With SGLT2 Inhibitors
por: TakallooBakhtiari, Asieh, et al.
Publicado: (2021)

Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient
por: Popli, Rakesh, et al.
Publicado: (2021)

Current Utilization Trends of SGLT-2 Inhibitors in Type 2 Diabetics With Heart Failure
por: Dhillon, Puneet, et al.
Publicado: (2021)

Euglycemic DKA in Patients on SGLT2 Inhibitor and Potentially Ketotic State
por: Khalifa, Maram, et al.
Publicado: (2021)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

SUN-177 House Of Carbs: The Path To Euglycemic Dka In Patients With Diabetes On Sglt2 Inhibitors
por: Islam, Julie, et al.
Publicado: (2019)

MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis
por: Chhabra, Sarah, et al.
Publicado: (2020)

Efficacy and Safety of SGLT2 Inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature
por: Shuster, Shirley, et al.
Publicado: (2021)

A Case of Euglycemic DKA With SGLT 2 Inhibitor Use- A Diagnostic and Therapeutic Dilemma
por: Nallu, Ravali, et al.
Publicado: (2021)

A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 Inhibitors
por: Marenych, Nadiia, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet
por: Hester, Joi C, et al.
Publicado: (2021)

Patient-Specific Risk Factors and Clinical Correlates of Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Co-Transporter-2 Inhibitors
por: Somagutta, Manoj Reddy, et al.
Publicado: (2021)

SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 Inhibitors and Keto-Diet
por: Castellanos-Diaz, Jessica, et al.
Publicado: (2020)

OR31-1 Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Diabetic Ketoacidosis: Clinical and Biochemical Characteristics of 21 Cases
por: Stamatiades, George, et al.
Publicado: (2019)

MON-LB123 Diagnosis and Management of Euglycemic DKA in the Setting of SGLT2 Inhibitor Use and Prostate Abscess
por: Rameshkumar, Naveen Sundar
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis Post Bariatric Surgery in Type II DM in the Setting of SGLT2-Inhibitor Use
por: Alfares, Khalid, et al.
Publicado: (2021)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

SUN-673 Development of Euglycemic Diabetic Ketoacidosis in a Patient with Well-Controlled Type 2 Diabetes Mellitus on a Sodium-Glucose Transporter 2 Inhibitor
por: Narang, Disha K, et al.
Publicado: (2020)

MON-694 EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i
por: Heckart, Jonathan Calvin, et al.
Publicado: (2020)

SUN-180 Successful Use of SGLT-2 Inhibitor Dapagliflozin in Three Patients with Renal Transplant and Diabetes: A Fruit for Thoughts
por: Elhadd, Tarik, et al.
Publicado: (2019)

SUN-181 Case Report: Rare Complication of SGLT2 Inhibitors Can Occur Only 10 Days after Starting the Medication
por: Elshimy, Ghada, et al.
Publicado: (2019)

SUN-155 Clinical Experience of SGLT2 Inhibitors in a Hispanic Population: Should We Consider Its Use as Add-On Treatment?
por: Zayas, Francisco, et al.
Publicado: (2019)

SUN-672 SGLT2 Inhibitor Reduces Hyperinsulinemia and Restores Pulsatile Growth Hormone Secretion in Obese MC4RKO Mice
por: Huang, Zhengxiang, et al.
Publicado: (2020)

SUN-176 Euglycemic Diabetic Ketoacidosis withSGLT2 Inhibitor Presenting as Chest Pain in a Patient with Coronary Artery Disease on a Ketogenic Diet
por: Dorcely, Brenda, et al.
Publicado: (2019)

Detecting Frailty in Elderly Type 2 Diabetes Mellitus (T2DM) Patients in the Southeast of Brazil
por: Ramos-Dias, João Carlos, et al.
Publicado: (2021)

Characterization of Patients With Type 2 Diabetes Mellitus and COVID-19
por: Videa, Elvin Omar, et al.
Publicado: (2021)

SARS-CoV-2 Infection Related Diabetes Mellitus
por: Beliard, Kara A, et al.
Publicado: (2021)

MON-LB029 The Influence of SGLT-2 Inhibitors and Other Glucose-Lowering Therapies on All-Cause Mortality Risk and Cardiovascular Outcomes in Older Patients with Newly Treated Type 2 Diabetes: A Population-Based Cohort Study
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Effects of Sodium Glucose Cotransporter 2 Inhibitor on Renal Renin-Angiotensin-Aldsoterone System
por: Takeda, Yoshiyu, et al.
Publicado: (2021)

LBODP041 Effects Of Sodium-glucose Co-transporter 2 Inhibitors (sglt-2 Inhibitors) On Adipokines And Inflammatory Biomarkers In Type2 Diabetic Patients
por: Kumtree, Phonphruet
Publicado: (2022)

SAT-LB118 Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Arao, Kevin A, et al.
Publicado: (2020)

OR14-6 The Role of the Angiopoietin-Tie2 Pathway in Microvascular Complications of Diabetes Mellitus
por: Brigell, Mitchell, et al.
Publicado: (2019)

MON-173 Vitamin D And Glycemic Control In Type 2 Diabetes
por: Jadoon, Nauman, et al.
Publicado: (2019)

SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor
por: Attia, Jonven, et al.
Publicado: (2019)

SAT-676 Pembrolizumab Induced Worsening Glycemic Control and DKA in Type 2 Diabetes Mellitus
por: Goud, Sarita, et al.
Publicado: (2020)

The Effect of Proton Pump Inhibitors on Insulin-Glucose Homeostasis in Patients With Type 2 Diabetes Mellitus
por: Verma, Vipin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4e6jsiq3oqb5afbfu1oil9bbll